Background: In a significant percentage of advanced non-small-cell lung cancer (NSCLC) patients, tumor tissue is unavailable or insufficient for genetic analyses. We prospectively analyzed if circulating-free DNA (cfDNA) purified from blood can be used as a surrogate in this setting to select patients for treatment with epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs).
Introduction
The clinical benefits of tyrosine kinase inhibitors (TKIs) in stage IIIB-IV non-small-cell lung cancer (NSCLC) patients carrying sensitizing mutations in the epidermal growth factor receptor (EGFR) gene are well established, and EGFR testing in tumor tissue has become a routine clinical practice [1] [2] [3] [4] [5] . However, a 5%-20% of advanced NSCLC patients cannot be biopsied or the tumor tissue in biopsies or cytological samples is insufficient for successful genetic analysis [6, 7] .
A number of studies (supplementary Tables S1 and S2 , available at Annals of Oncology online) have evaluated, in an exploratory manner, whether the cfDNA isolated from serum or plasma of advanced NSCLC patients can be used to reliably determine EGFR mutations and three large meta-analyses, including 1591-2605 samples, have reported pooled sensitivity rates of 61%-67% with 90%-97% specificities [8] [9] [10] . The European Medicine Agency has authorized the administration of first-line TKIs based exclusively on EGFR positivity detected in the cfDNA of patients with no tumor tissue available [11] and the FDA has also recently expanded to plasma cfDNA the use of the COBAS Mutation Test v2 as a companion kit for erlotinib [12] .
However, all the published studies on EGFR testing in cfDNA have focused on selected populations of advanced NSCLC patients, usually with paired biopsies and coming from clinical trials, with analyses generally carried out in a retrospective manner. To the best of our knowledge, there are no reports in the literature of patients treated with TKIs based exclusively on a positive EGFR result in blood. In consequence, the performance and clinical utility of prospective EGFR testing in the cfDNA from unselected advanced NSCLC patients remains to be established.
Here, we present the results of the EGFR blood testing carried out in 1138 advanced NSCLC patients with no tumor tissue and the response data to EGFR-TKIs of a cohort of patients treated solely on the basis of positivity in blood. Our work is the first report of large scale, prospective EGFR screening in the cfDNA of unselected stage IIIB-IV NSCLC and demonstrates that blood testing can be used to select patients for EGFR-TKI therapy when tumor tissue is not available or insufficient for genetic analysis.
Methods Patients
The blood from 1138 advanced NSCLC patients collected in 119 Spanish hospitals was prospectively tested for EGFR mutations (supplementary Table S3 and Figure S1 , available at Annals of Oncology online). Patients with no tumor tissue available for genetic analyses were included in the study, which was carried out in accordance with the principles of the Declaration of Helsinki. Written informed consent was obtained from all patients and documented. The information prospectively collected from each patient was limited to gender, smoking status, histology and reason for not having tissue available for testing. Clinical data could be retrospectively collected in a subset of 18 EGFR mutant patients.
EGFR mutation testing in blood by PNA-Q-PCR Paired serum and plasma samples (10 ml) were collected in Vacutainer tubes (BD, Plymouth, UK) in each participating hospital, centrifuged and sent to a central laboratory. Purification of cfDNA from serum and plasma (1.2 ml) was carried out with the QIAsymphony V R DSP Virus/Pathogen Midi Kit using a QIAsymphony robot (Qiagen). EGFR mutations were determined in the serum and plasma cfDNA by a 5 0 -nuclease real-time quantitative PCR (Taqman V R ) in the presence of PNAs (PNA-Q-PCR) (supplementary Figure S2 , available at Annals of Oncology online).
Validation of the PNA-Q-PCR assay
The preclinical validation of the assay was carried out using serial dilutions of DNA from cell lines (see supplementary material, available at Annals of Oncology online). In order to determine the diagnostic specificity and sensitivity of the PNA-Q-PCR assay for EGFR sensitizing mutations, we used archival cfDNA from 268 lung cancer patients from Quiron Dexeus University Hospital with paired tumor tissue previously genotyped. The blood of 112 additional NSCLC patients at the time to progression to EGFR-TKIs from the same Hospital was used to compare the PNA-Q-PCR assay with the Therascreen EGFR Plasma RGQ PCR Kit V R (Qiagen, Hilden, Germany).
Results

Assay description and validation
We developed an assay for EGFR mutation testing in cfDNA purified from serum and plasma, based on a Q-PCR in the presence of PNAs designed to inhibit the amplification of the wildtype alleles (PNA-Q-PCR). The assay, which can determine the most prevalent somatic mutations in the EGFR gene (supplementary Table S4 , available at Annals of Oncology online), is simple, sensitive, has a short turnaround time (24-48 h) and allows estimation of the absolute and relative quantities of the mutant alleles (supplementary Figure S3 , available at Annals of Oncology online). It is also inexpensive; the cost of the consumables and reagents needed to analyze one blood sample (serum and plasma) is around 60 euro. Blood from 268 advanced NSCLC patients at presentation with paired tumor tissue was used for the diagnostic validation of the assay (supplementary Table S5 , available at Annals of Oncology online), which demonstrated a sensitivity of 75.9% (CI ¼ 68.9-81.7) and a specificity of 100% (CI ¼ 96.2-100) for EGFR sensitizing mutations. Sensitivity in plasma (70.0%; CI ¼ 62.7-73.4) was higher than in serum (57%; CI ¼ 49.5-64.3) while specificity was 100% in both cases (supplementary Table S6 , available at Annals of Oncology online).
Regarding the p.T790M, we first tested the blood of a subset (n ¼ 167) of the advanced NSCLC patients at presentation mentioned above. The resistance mutation was not detected in any case (100% sensitivity, CI ¼ 99.1-100). We next examined the blood of 112 EGFR-mut patients after progression to TKIs and the p.T790M was present in 38 (33.9%). These 112 samples were also used to compare the PNA-Q-PCR and Therascreen assays. Concordance for EGFR sensitizing mutations was 0.90 (CI ¼ 0.83-0.94; Cohen's j 0.78) (supplementary Table S7 , available at Annals of Oncology online). The p. Table S8 , available at Annals of Oncology online). Two patients p.T790M positive by PNA-Q-PCR and negative by Therascreen had a rebiopsy available; mutation was present in both cases.
Clinical characteristics of patients at presentation
During the period June 2012 to April 2016, 1033 advanced NSCLC patients at presentation were prospectively screened (supplementary Table S3 , available at Annals of Oncology online). Of them, 535 (52%) could not be biopsied and 498 (48%) had biopsies; in all cases tumor tissue was insufficient or nonexistent in both cytological samples and/or biopsies. Seven cases (0.7%) were not assessable due to insufficient blood volume (supplementary Figure S1 , available at Annals of Oncology online). Among the remaining 1026 assessable patients, there was a majority of men (55.8%), and former smokers (46.8%) ( Table 1) .
Mutations in exons 19 and 21 of the EGFR gene were detected in the cfDNA of 113/1026 patients at presentation (11.0%) ( Table 1) , being prevalent in female (66.4%) and never smokers (63.7%). Regarding the type of mutation, 75 patients had exon 19 deletions and 38 exon 21 point mutations. Of those, 35 were positive for the p.L858R and 3 for the p.L861Q mutation. Regarding exon 19, the 15-pb deletion was the most frequent alteration (Table 1) . Finally, starting in May 2015, all samples were screened for the p.T790M, which was not detected in any of the 439 pretreatment blood samples analyzed.
Characterization of the cfDNA samples at presentation
The concentration of DNA was measured by Qubit V R in a subset of EGFR-mut (n ¼ 40) and EGFR-wt (n ¼ 40) blood samples. The median concentration of cfDNA in sera and in EGFR-mut patients was higher but the differences did not reach significance in a Mann-Whitney U test (supplementary Table S9 , available at Annals of Oncology online).
The absolute concentration of the mutated allele could be determined in 145 positive serum and plasma samples, corresponding to 90 EGFR-mut patients. It ranged from 2.5 to 2528.5 pg/ml and the distribution observed had an inverted 'J' profile, with >60% of cfDNA samples having <10 pg mutant genomes/ml. Median concentration was higher in plasmas than in sera (5.4 versus 3.2) but the difference did not reach significance ( Figure 1 ).
The mutation load was determined in 149 serum and plasma samples from 91 EGFR-mut patients. It ranged from 0.005% to 43.87% and the distribution observed shifted to Gauss-like when a logarithmic transformation was applied, with >50% of the samples with values below 0.25%. Median mutation load was higher in plasmas (0.23% versus 0.12% in sera) and in samples positive for exon 19 deletions (0.26% versus 0.07% for exon 21) but the differences only reached statistical significance for exon 19 versus exon 21 mutations (Figure 1 ). The mutation load in the positive samples showed a statistically significant correlation with the absolute concentration of mutant genomes (Spearman's q ¼ 0.43, P < 0.001).
EGFR mutations in cfDNA at progression to TKIs
The peripheral blood of 105 advanced NSCLC patients after progression to EGFR-TKIs was prospectively screened from May 2015 to April 2016 (Table 1 ; supplementary Figure S1 , available at Annals of Oncology online). Sensitizing mutations were detected in 59 cases (56.2%) while the resistance mutation p.T790M was present in 37 patients (35.2%). Of those, the p.T790M appeared alone once, and together with exon 19 and exon 21 mutations in 30 and 6 cases, respectively. Similarly to the sensitizing mutations, the absolute concentrations and allelic fractions of the p.T790M showed a wide variation among the positive patients (Figure 2 ). Absolute and relative concentrations of the sensitizing mutations in blood were significantly higher in positive patients progressing to TKIs than in those at presentation (Figure 2 ).
Clinical outcome to TKIs
We retrospectively collected clinical information of 18 patients treated with TKIs based exclusively on the results of the EGFR testing in blood (Table 2 ). Of those, 13 (72.2%) had partial responses to EGFR-TKI treatment. Data about the duration of the response could only be obtained in 8 patients; the range was 5-18 months and the median PFS 11 months. The two p.L858R patients progressed after 5 and 8 months versus 7-NR months of the 6 patients harboring exon 19 mutations. Some of the patients identified as EGFR positive, based solely on the results of the Q-PNA-PCR assay, showed remarkable responses to targeted therapy ( Figure 3 ).
Discussion
Here, we present the prospective testing for EGFR mutations in the cfDNA of 1033 unselected advanced NSCLC patients at presentation and 105 after progression to TKIs, proceeding from 119 Spanish hospitals, during a period of 46 months. Patients tested could not be biopsied, or the amount of cancer cells in biopsies or cytological samples was insufficient, and blood was the only material available. When this large scale testing was started, there were no commercial kits to determine EGFR mutations in liquid biopsies. In consequence, a PNA-Q-PCR assay for the detection of mutations in exons 19, 20 (p.T790M) and 21 (p.L858R and p.L861Q) was developed [13] and fully validated. The assay is simple, not more expensive than tissue analysis, has a short turnaround time and its limits of detection, sensitivity (75.9%) and specificity (100%) are in the range of other reported methodologies (supplementary Table S1 , available at Annals of Oncology online). The main limitation of the assay is that it cannot detect the relatively infrequent mutations in exon 18 of EGFR.
Of 1033 blood samples at presentation included in the study, only 7 were lost due to pre-processing issues. Sensitizing mutations were detected in 11% of cases and, although most samples were from men and former smokers, patients positive in cfDNA were predominantly women and non-smokers. [1, 3] . These results confirmed the robustness of both the PNA-Q-PCR technique used and the preanalytical steps implemented, which are fundamental for a successful genetic testing in liquid biopsies [14] . Plasma and serum were collected in standard tubes, immediately centrifuged in site to avoid white cell lysis and sent to the central laboratory.
Shipping time never exceeded 24 h and cfDNA was purified using an automatic extractor, which guaranteed a high throughput and reduced contaminations to a minimum. Regarding the 105 patients relapsing to EGFR-TKI therapy, we detected the p.T790M mutation in the blood of 37 (35.2%) a frequency significantly lower than the 49%-62% reported in rebiopsies in Western countries [15] [16] [17] . One factor that can explain this finding is that our PNA-Q-PCR assay, similarly to other techniques for EGFR testing in blood (supplementary Tables S1  and S2 , available at Annals of Oncology online), might have a lower sensitivity for the p.T790M. At any rate, the 35% positivity for this mutation found in the blood of patients relapsing to TKIs compares favorably with the 22%-30% reported with Cobas V R and Therascreen TM . These two tests are also based on Q-PCR and show specificities versus tumor tissue close to 100%. Regarding other techniques, the frequencies of detection of the p.T790M in blood at progression are 18%-52% for droplet digital PCR, 31%-66% for BEAMing and 78% for short footprint mutation enrichment NGS (supplementary Table S2 , available at Annals of Oncology online). However, the specificities of these techniques are only in the 50%-90% range.
We observed 1000-and 10 000-fold variations in the absolute and relative concentrations of EGFR mutations in cfDNA, respectively. More than 50% of samples had >10 pg mutated genomes/ml and mutation loads below 0.25%, highlighting the need for good analytical sensitivities when analyzing EGFR mutations in cfDNA. The variations in the concentrations of EGFR mutations in blood have been described to depend not only on the tumor burden, stage or anatomical proximity to vasculature, but also on the molecular heterogeneity of the tumor. At this respect, the proportion of EGFR mutated alleles in tumor tissue also shows some variability (10%-60%) which, together with the presence of accompanying mutations, can affect treatment outcomes [18] . It remains to be investigated whether the mutation load and the detection of additional mutations in the blood of EGFR-positive patients might also have prognostic implications.
In our study, the sensitivity of mutation detection in plasma was higher, as reported for other techniques [19, 20] . Serum yielded more cfDNA than plasma but the absolute quantities of mutation were higher in plasma. As a result, the mutation load was lower in serum cfDNA, a fact that may explain the differences in detection rates. However, mutations were found exclusively in serum in 8% of the positive patients; who would have been informed as ineligible for targeted therapies if only plasma had been used.
We could retrospectively collect the clinical data of 18 patients treated first line with TKIs based exclusively on a positive EGFR result in blood. The percentage of partial responses was 72% and the median PFS 11 months. Despite the limited size of this cohort, these clinical outcomes are indistinguishable from the 64% to 71% and the 10 to 14 months reported for European advanced NSCLC patients treated with first-line TKIs with EGFR mutations detected in tumor tissue [1, 3] .
In summary, we have presented the results of the prospective testing of EGFR mutations in the blood of 1033 advanced NSCLC patients at presentation and 105 after progression. We have demonstrated for the first time that such a large-scale testing of an unselected population is feasible, and that the characteristics and clinical outcomes to TKI treatment of the EGFR-mutated patients identified exclusively in blood are undistinguishable from those positive in tumor tissue. 'Liquid' biopsies will never replace tumor biopsies, which constitute unique sources of information that cannot be obtained by any other means. However, our results demonstrate that prospective EGFR analysis in blood can be used to select patients for TKI therapy when no tumor tissue is available for genetic testing.
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